论文部分内容阅读
本研究检测初治淋巴瘤患者血浆中血管生成相关因子VEGF-C、VEGF-D、VEGFR-2、VEGFR-3的表达水平,探讨其与淋巴瘤临床特点及预后的相关性,寻找指导淋巴瘤抗血管靶向治疗及判断预后的有价值的指标和因素。应用酶联免疫吸附测定的方法检测86例初治淋巴瘤患者血浆中VEGF-C、VEGF-D、VEGFR-2、VEGFR-3的表达水平。结果表明,多因素分析结果显示,VEGF-C在非霍奇金淋巴瘤患者中呈低表达水平,而在霍奇金淋巴瘤患者中表达水平较高;VEGFR-2在年龄>60岁淋巴瘤患者中表达较高;VEGF-D在IPI>2分的患者组中表达较低。单因素分析显示,VEGF-D在IPI>2分患者组中呈低水平表达;VEGF-D、VEGF-C在无B症状组高水平表达。因子间的关联性分析表明,VEGF-D与VEGFR-2、VEGFR-3的表达水平呈正相关。结论:VEGF-C、VEGF-D、VEGFR-2、VEGFR-3在淋巴瘤的发病中具有重要作用,可作为细化指导淋巴瘤抗血管靶向治疗、了解病情、判断预后的指标。
This study was to detect the expression of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in the plasma of patients with newly diagnosed lymphoma and to explore its correlation with the clinical features and prognosis of lymphoma. Anti-vascular target therapy and prognosis of the valuable indicators and factors. The expression of VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 in 86 patients with newly diagnosed lymphoma was detected by enzyme linked immunosorbent assay. The results showed that the results of multivariate analysis showed that VEGF-C was low in non-Hodgkin’s lymphoma patients and higher in Hodgkin’s lymphoma patients. VEGFR-2 was found in patients with lymphoma> 60 years old The expression was higher in patients; VEGF-D was lower in patients with IPI> 2 points. Univariate analysis showed that VEGF-D was low level in patients with IPI> 2, VEGF-D and VEGF-C were expressed at high level in patients without B symptoms. Correlation analysis showed that there was a positive correlation between VEGF-D and the expression of VEGFR-2 and VEGFR-3. CONCLUSION: VEGF-C, VEGF-D, VEGFR-2 and VEGFR-3 play an important role in the pathogenesis of lymphoma and can be used as an index to guide the anti-vascular targeted therapy of lymphomas in detail.